Genetic Influences on Response to Drug Treatment for Major Psychiatric Disorders / edited by Janusz K Rybakowski, Alessandro Serretti
Contributor(s): SpringerLink (Online service)
| Rybakowski, Janusz K., editor literario
| Serretti, Alessandro., editor literario
Material type:
E-bookPublisher: Cham : Springer International Publishing Imprint Adis, 2016Edition: 1st ed.Description: 1 recurso en línea (IX, 117 páginas) :.ISBN: 9783319270401.Subject: Medicina
| Item type | Current library | Collection | Call number | Copy number | Status | Date due | Barcode | Item holds | |
|---|---|---|---|---|---|---|---|---|---|
LIBRO-E NO PRÉSTAMO
|
Madrid Digital Acceso Electrónico (UEM) | Ciencias de la Salud | RC435 .G464 2016 EB (Browse shelf(Opens below)) | .i11589425 | Acceso electrónico | eBOOK .i11589425 |
1. Pharmacogenetics of the Efficacy of Antipsychotic Drugs in Schizophrenia -- 2. Pharmacogenetics of Serious Antipsychotic Side-Effects -- 3. Pharmacogenetics of the Efficacy and Side Effects of Antidepressant Drugs -- 4. Genomic Studies of Treatment Resistance in Major Depressive Disorders -- 5. Complementation of Pharmacogenetics with Biomarkers and Neuroimaging in Major Depression -- 6. Pharmacogenetics of Mood Stabilizers -- 7. Practical Application of Pharmacogenetics of Antipsychotic, Antidepressant and Mood-Stabilizing Drugs.
Written by global experts, this book provides a modern comprehensive insight into the pharmacogenetics of treatment of major psychoses: schizophrenia, bipolar disorder and depression. The pharmacogenomics of three categories of the most important psychiatric drugs, antipsychotics, antidepressants and mood stabilizers, has been updated and reviewed. Some promising directions and perspectives for future research in pharmacogenetics in major psychoses are indicated. They are, among others, connected with the development of new methods in molecular genetics and with linking pharmacogenetics assessment with biomarkers, including neuroimaging ones. Finally, the attempts to use pharmacogenetics of antipsychotic, antidepressant and mood-stabilizing drugs in practice are presented. New pharmacogenetic tools may greatly contribute to introducing personalized medicine into psychiatric clinical practice.
There are no comments on this title.